
Septerna Inc (SEPN) Stock Forecast & Price Target
Septerna Inc (SEPN) Analyst Ratings
Bulls say
Septerna Inc. presents a compelling investment opportunity with a current enterprise value of approximately $430 million, which suggests significant upside potential, possibly 8-10 times the current share price, particularly if its partnership with Novoproves proves successful. The company's clinical pipeline, including promising candidates like SEP-631, has the potential to achieve blockbuster status similar to established therapies, thereby enhancing long-term revenue prospects. Furthermore, Septerna's strategic collaboration with Novo Nordisk allows for access to the expansive obesity market in a low-risk and capital-efficient manner, strengthening its long-term value creation opportunities.
Bears say
The financial outlook for Septerna Inc appears negative due to several inherent risks, primarily related to potential delays and setbacks in the clinical development of its candidates, particularly SEP-631. The company faces significant partnership risks, particularly in its relationship with Novo Nordisk, which could further impact its ability to secure approvals for key drug candidates. Additionally, lower-than-expected market penetration rates and the possibility of long-term dilution pose further challenges to the company’s financial stability and valuation.
This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.
Septerna Inc (SEPN) Analyst Forecast & Price Prediction
Start investing in Septerna Inc (SEPN)
Order type
Buy in
Order amount
Est. shares
0 shares